Deutsche Bank lowered the firm’s price target on Bristol Myers to $45 from $53 and keeps a Hold rating on the shares as part of a Q2 earnings preview. Prescription trends for Bristol’s growth portfolio for Q2 looks light and may weigh on the shares, the analyst tells investors in a research note. The firm says the company’s pipeline “is still a work in progress.” It believes capitalizing on Bristol Myers’ “attractive valuation” in the near- to mid term may be challenging until line of sight to a earnings and sales trough is clear.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Options Volatility and Implied Earnings Moves This Week, July 22 – July 26, 2024
- Bristol Myers’ Opdivo combination in carcinoma receives EMA validation
- Bristol Myers initiated with a Sell at Bocom
- Bristol Myers Squibb call volume above normal and directionally bullish
- Bristol Myers price target lowered to $43 from $47 at UBS